Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of laggera plant abstract in inhibiting herpes simplex virus and hepatitis B virus

A technology of plant extracts and hepatitis B virus, applied in the field of medicine, can solve problems such as drug resistance, high price, and adverse effects

Inactive Publication Date: 2010-07-14
ZHEJIANG HISUN PHARMA CO LTD
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinically, the treatment plan can only achieve the inhibition of HBV replication and secondary infection. The most important drug is still nucleoside drugs, the earliest is acyclovir, which has no negative effect on hepatitis B surface antigen (HBsAg), and has no negative effect on hepatitis B e antigen (HBeAg). and hepatitis B virus deoxyribonucleic acid (HBVDNA) negative conversion rates were 25.0% and 27.6%, recently developed many new nucleoside drugs, including lamivudine (3-TC), entecavir, adefovir (ADV), etc. Although they can effectively control the disease, one is expensive, and the other is drug resistance and rebound in different degrees after long-term use.
The third is the relatively obvious and well-known adverse effects of long-term use of nucleoside drugs
After reviewing the literature, so far, there is no information about the treatment of Herpes Simplex Virus (HSV-1 and / or HSV-2) and Hepatitis B Virus (HBV) with Caffeoylquinic Acid Compounds. Reports on Infectious Diseases and Preparation of Antiviral Drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of laggera plant abstract in inhibiting herpes simplex virus and hepatitis B virus
  • Use of laggera plant abstract in inhibiting herpes simplex virus and hepatitis B virus
  • Use of laggera plant abstract in inhibiting herpes simplex virus and hepatitis B virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015]Example 1 : Inhibition of HSV-1 by extracts of plants of the genus Hexaphyllum containing caffeoylquinic acid compounds:

[0016] 1.1 Cell culture and virus subculture: Culture Vero cells in RPMI1640 medium containing 10% inactivated calf serum, 100U / ml penicillin and 100μg / mL at 37°C, 5% CO 2 , cultured in an incubator with 100% relative humidity. Add HSV-1 to the long-lived Vero cell flask, set at 37°C, 5% CO 2 , cultivated in an incubator with 100% relative humidity, collected the culture supernatant, and stored it at low temperature.

[0017] 1.2 Experimental method:

[0018] MTT method was used to measure the inhibitory effect of the plant extract of Hexagonal genus containing caffeoylquinic acid compounds on the growth of Vero cells: the Vero cells in the logarithmic growth phase were taken, and the cells were diluted to 1 × 10 with medium. 5 / mL, seeded in 96-well cell culture plate, 100 μL per well, at 37°C, 5% CO 2 After culturing in an incubator with 100% r...

Embodiment 2

[0025] Example 2: Inhibition test of HSV-2 by extracts of plants of the genus Hexaphyllum containing caffeoylquinic acid compounds:

[0026] 2.1 Cell culture and virus passage: Same as Example 1.

[0027] 2.2 Experimental method:

[0028] Adopt MTT method, calculate the half maximal inhibitory concentration (TD) to cell growth with the method of embodiment one 50 ), the inhibitory effect on virus growth (IC 50 ), and the sample therapeutic index (TI).

[0029] 2.3 Experimental results: the results are shown in Table 1, the plant extracts of the genus Hexaphyllum containing caffeoylquinic acid compounds can significantly inhibit the replication of HSV-2. Its half inhibitory concentration to HSV-2 is 90.05 μg / mL, and its therapeutic index is 11.10.

Embodiment 3

[0030] Example 3: Inhibition test of Hepatitis B virus deoxyribonucleic acid (HBVDNA) containing caffeoyl quinic acid compounds of the plant extracts of the genus Hepatitis:

[0031] 3.1 Instruments and reagents: PE7700 automatic fluorescent PCR instrument, produced by Perkin Elmer Company of the United States; HBVDNA fluorescence quantitative detection kit was provided by Da’an Gene Diagnostic Center of Sun Yat-sen Medical University; fetal bovine serum, DMEM, G418, and trypsin were all purchased from Gibco Company.

[0032] 3.2 In vitro cell model: HepG 2.2.15 cell line was provided by Zhejiang University Traditional Chinese Medicine and Natural Medicine Laboratory. HepG2.2.15 cells were inoculated in DMEM culture medium (containing 10% fetal bovine serum, 380ug / mLG418) and placed in 5% Cultured in CO2 37°C incubator.

[0033] 3.3 Drug effect: HepG 2.2.15 cells were digested with trypsin digestion solution and diluted to 8×10 4 / mL suspension, inoculated in a 96-well cell...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention involves novel drug use of six-rowed chrysanthemum plant extracts which is used to treating herpes simplex virus (type 1 and / or type 2) and various disease caused by hepatitis B virus infection. The six-rowed chrysanthemum plant extracts is prepared by six-rowed chrysanthemum plant fresh or dry goods through the refining of alcohol-water extraction, column chromatography, alcohol solvent elution, the amount of caffeoyl guinic acid chemical compound is below 30%. The six-rowed chrysanthemum plant extracts prepared in the invention has significant function of inhibiting herpes simplex virus with type 1 (HSV-1), herpes simplex virus type 2 (HSV-2) and hepatitis B virus (HBV) replication, and can reduce effectiveness of HBV e antigen (HBeAg) in the HepG 2.2.15 cell lines, it can be used for treatment various disease caused by said correlate virus infection.

Description

technical field [0001] The present invention relates to the field of medical technology, in particular, the present invention relates to extracts containing caffeoylquinic acid compounds in plants of the genus Hexaphyllum, which can be expected to have therapeutic effect on type 1 and type 2 herpes simplex virus and hepatitis B virus. Medicinal use of drugs for various conditions caused by infections. Background technique [0002] Viral infectious diseases are the great enemies that threaten human diseases. Research shows that 60% of diseases are caused by viral infections, and viral infectious diseases have become one of the main causes of population death in our country. The continuous emergence of new viruses, such as human immunodeficiency virus, atypical pneumonia virus, etc., puts forward higher requirements for the development of antiviral drugs. There is still a lack of specific drugs for the treatment of viral infectious diseases. Currently, the clinically used dru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/287A61K9/00A61P1/16A61P31/20
Inventor 赵昱周长新李海波于荣敏巫秀美
Owner ZHEJIANG HISUN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com